Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? - Wikidata - wikimedia - TriplyDB

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

http://www.wikidata.org/entity/Q46823146

about

A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease A systematic review of biomarkers for disease progression in Parkinson's disease Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease.Experimental designs for small randomised clinical trials: an algorithm for choice.Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?Milestones in movement disorders clinical trials: advances and landmark studies.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease.Long-term efficacy of rasagiline in early Parkinson's disease.Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.Disease modification in Parkinson's disease.

P2860

Q27311651-C95FC96C-1786-4464-88B0-D3DF1663E364 Q30455202-A883097B-F664-4F00-9D70-092A896CF4F3 Q34027880-4D53BD6F-D44B-445C-A149-6B38070D8330 Q35048310-FD166C4B-99F3-41F1-B873-29E52A8D8651 Q36793954-A292B627-7473-4E49-8E24-79E1AFC80BE4 Q37865446-809178EC-12B1-46EB-9823-DB166C424525 Q37882584-D5427431-3B6D-4613-B23E-FF468C75C91F Q38206403-C513A7C4-1CAC-4F30-B9B3-1B9854504044 Q41438847-420DB6AC-7CC7-4328-96A1-94EC57AA0C46 Q42661912-53DD17F6-3552-406A-9728-D2C1647C6CB1 Q43489430-E5EB5643-321C-4740-8056-19EB6B68157A Q44713421-E3EE8A36-B3BF-49AC-8D45-1B0B620A191E

P2860

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

http://www.wikidata.org/entity/Q46823146

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Are delayed-start design trial ...... disease fundamentally flawed?

@en

Are delayed-start design trial ...... disease fundamentally flawed?

@nl

type

label

Are delayed-start design trial ...... disease fundamentally flawed?

@en

Are delayed-start design trial ...... disease fundamentally flawed?

@nl

prefLabel

Are delayed-start design trial ...... disease fundamentally flawed?

@en

Are delayed-start design trial ...... disease fundamentally flawed?

@nl

P1433

Q46823146-CA1E3042-78DB-44B5-B089-11C597638FD1

P1476

Q46823146-910B27CC-5FFF-46A1-87E6-780640A0321B

P2093

Q46823146-233009C2-FDBF-4F55-B916-886540DBCF8A

P2860

Q46823146-026162C7-3A10-4370-8593-CCD7BE37979B

Q46823146-0290316C-0FEE-4C27-ABD1-D22DBACD94E0

Q46823146-0B0BED0E-6A81-4004-A774-6BAC14CBE95F

Q46823146-0CD65DCC-EA36-4E91-96AF-CEF8A2A18150

Q46823146-0F8ACDEE-E392-460A-8C28-7D04BAB2379D

Q46823146-1ACBBD02-7DD1-46D0-B89A-67B79D7613DA

Q46823146-324BCD3E-A632-4697-81F3-49557C08716C

Q46823146-5662D3B9-BAC2-4DBF-BBBF-9BED81E61A66

Q46823146-582F8649-EFAE-4BC6-884A-15D1423A8614

Q46823146-7FC2CFC0-CE9E-4D7B-90F1-36DEC586F050

P304

Q46823146-21FD1D18-14D3-483C-9AA3-1D15C39C15E4

P31

Q46823146-6E49BCF4-CB12-48D1-8A53-5E004C607BA4

P356

Q46823146-67F07AD6-2081-4E72-9EAF-38A8F4F15C10

P407

Q46823146-26763E69-4DD2-4EE6-B6FA-89BC74F35841

P433

Q46823146-0FA01439-6693-423D-B972-665F2C4F954E

P478

Q46823146-6F602522-B329-41AB-A55A-480684F875D6

P50

Q46823146-95898519-F760-4ECA-B462-D8703944DEC6

P577

Q46823146-93B2AFDF-B96B-450E-907D-73757CD5FB99

P698

Q46823146-0E4453F4-CE03-432C-B8FC-5137850FC186

P921

Q46823146-06B9DA97-3CB3-4E27-A1A5-B6A9D6B64CF9

P356

P1433

Movement Disorders

P1476

Are delayed-start design trial ...... disease fundamentally flawed?

@en

P2093

Carl E Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

Dopamine agonist monotherapy in Parkinson's disease

Ageing and Parkinson's disease: substantia nigra regional selectivity

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

Levodopa and the progression of Parkinson's disease.

Evaluating drug treatments for Parkinson's disease: how good are the trials?

A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

P304

784-789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.21918

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18175348

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease